Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Arrhythmias

  Free Subscription


Articles published in J Thromb Thrombolysis

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    June 2021
  1. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    PubMed     Abstract available


    May 2021
  2. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    PubMed     Abstract available


  3. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    PubMed     Abstract available


    April 2021
  4. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    PubMed     Abstract available


  5. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    PubMed     Abstract available


    February 2021
  6. LIVNEH N, Braeken D, Drozdinsky G, Gafter-Gvili A, et al
    Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy.
    J Thromb Thrombolysis. 2021 Feb 1. pii: 10.1007/s11239-021-02393.
    PubMed     Abstract available


    January 2021
  7. FENG Y, Pai CW, Seiler K, Barnes GD, et al
    Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study.
    J Thromb Thrombolysis. 2021 Jan 3. pii: 10.1007/s11239-020-02358.
    PubMed     Abstract available


    November 2020
  8. DING WY, Lip GYH, Bartoletti S, Morrison L, et al
    Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data.
    J Thromb Thrombolysis. 2020 Nov 9. pii: 10.1007/s11239-020-02333.
    PubMed     Abstract available


    October 2020
  9. MARIANI MV, Magnocavallo M, Straito M, Piro A, et al
    Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
    J Thromb Thrombolysis. 2020 Oct 12. pii: 10.1007/s11239-020-02304.
    PubMed     Abstract available


    September 2020
  10. PIAZZA G, Hurwitz S, Carroll B, Goldhaber SZ, et al
    Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients.
    J Thromb Thrombolysis. 2020 Sep 30. pii: 10.1007/s11239-020-02296.
    PubMed     Abstract available


  11. HUANG K, Zha M, Gao J, Du J, et al
    Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 Sep 12. pii: 10.1007/s11239-020-02269.
    PubMed     Abstract available


    July 2020
  12. MOHAMED MFH, Elewa H, Mubasher M, Danjuma M, et al
    Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients.
    J Thromb Thrombolysis. 2020 Jul 31. pii: 10.1007/s11239-020-02238.
    PubMed    


  13. CAPPELLARI M, Forlivesi S, Zucchella C, Valbusa V, et al
    Factors influencing cognitive performance after 1-year treatment with direct oral anticoagulant in patients with atrial fibrillation and previous ischemic stroke: a pilot study.
    J Thromb Thrombolysis. 2020 Jul 29. pii: 10.1007/s11239-020-02233.
    PubMed     Abstract available


  14. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.
    PubMed    


    June 2020
  15. AMIN A, Keshishian A, Dina O, Dhamane A, et al
    Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population.
    J Thromb Thrombolysis. 2020 Jun 20. pii: 10.1007/s11239-020-02161.
    PubMed     Abstract available


  16. TZEIS S, Savvari P, Skiadas I, Patsilinakos S, et al
    Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 Jun 9. pii: 10.1007/s11239-020-02167.
    PubMed     Abstract available


    May 2020
  17. LV MN, Zheng XC, Zhang HQ, Xu FD, et al
    Comparison of clinical performance of four gastrointestinal bleeding risk scores in Chinese patients with atrial fibrillation receiving oral anticoagulants.
    J Thromb Thrombolysis. 2020 May 27. pii: 10.1007/s11239-020-02152.
    PubMed     Abstract available


  18. SANTORO F, Brunetti ND, Rillig A, Reissmann B, et al
    Stroke and left atrial thrombi after cryoballoon ablation of atrial fibrillation: incidence and predictors. Results from a long-term follow-up.
    J Thromb Thrombolysis. 2020 May 23. pii: 10.1007/s11239-020-02148.
    PubMed     Abstract available


  19. WANG CL, Wu VC, Huang YT, Chen YL, et al
    Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 May 14. pii: 10.1007/s11239-020-02135.
    PubMed     Abstract available


  20. DUARTE RCF, Rios DRA, Figueiredo EL, Caiaffa JRS, et al
    Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
    J Thromb Thrombolysis. 2020 May 6. pii: 10.1007/s11239-020-02126.
    PubMed     Abstract available


  21. NEHAJ F, Sokol J, Ivankova J, Mokan M, et al
    Edoxaban affects TRAP-dependent platelet aggregation.
    J Thromb Thrombolysis. 2020;49:578-583.
    PubMed     Abstract available


    April 2020
  22. ZHANG L, Yan X, Fox KAA, Willmann S, et al
    Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2020 Apr 23. pii: 10.1007/s11239-020-02077.
    PubMed     Abstract available


  23. LIU W, Xiong N, Xie K, Wu B, et al
    A stricter control of low-density lipoprotein is necessary for thrombosis reduction in "lower thrombosis risk" patients with atrial fibrillation: a multicenter retrospective cohort study.
    J Thromb Thrombolysis. 2020 Apr 13. pii: 10.1007/s11239-020-02110.
    PubMed     Abstract available


  24. TOSELLI M, Bosi D, Benatti G, Solinas E, et al
    Left atrial appendage closure: a balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation.
    J Thromb Thrombolysis. 2020 Apr 8. pii: 10.1007/s11239-020-02097.
    PubMed     Abstract available


  25. BO M, Brunetti E, Gibello M
    Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.
    J Thromb Thrombolysis. 2020;49:499-500.
    PubMed    


    March 2020
  26. PETERSON BE, Bhatt DL
    Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention.
    J Thromb Thrombolysis. 2020 Mar 12. pii: 10.1007/s11239-020-02081.
    PubMed     Abstract available


  27. UENO EI, Fujibayashi K, Sawaguchi J, Yasuda Y, et al
    Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
    J Thromb Thrombolysis. 2020 Mar 12. pii: 10.1007/s11239-020-02079.
    PubMed     Abstract available


    February 2020
  28. NOMURA E, Takemaru M, Himeno T, Kono R, et al
    Clinical features and efficacy of reperfusion therapy in minor ischemic stroke patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 Feb 11. pii: 10.1007/s11239-020-02057.
    PubMed     Abstract available


  29. BERNSTEIN MR, John L, Sciortino S, Arambages E, et al
    Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project.
    J Thromb Thrombolysis. 2020;49:316-320.
    PubMed     Abstract available


  30. VEDOVATI MC, Mosconi MG, Isidori F, Agnelli G, et al
    Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
    J Thromb Thrombolysis. 2020;49:251-258.
    PubMed     Abstract available


    January 2020
  31. KHEIRI B, Simpson TF, Stecker EC, Osman M, et al
    Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials.
    J Thromb Thrombolysis. 2020 Jan 24. pii: 10.1007/s11239-020-02041.
    PubMed    


  32. JONES MJ, Eudaley ST, Moye RA, Hodge TA, et al
    Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
    J Thromb Thrombolysis. 2020 Jan 4. pii: 10.1007/s11239-019-02028.
    PubMed     Abstract available


  33. MAMELI A, Schirru P, Porru M, Marongiu F, et al
    Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.
    J Thromb Thrombolysis. 2020;49:136-137.
    PubMed    


    December 2019
  34. TAN BY, Leow AS, Teoh HL, Gopinathan A, et al
    High incidence of under-treated atrial fibrillation: perspectives from an Asian Stroke Endovascular Thrombectomy Registry.
    J Thromb Thrombolysis. 2019 Dec 13. pii: 10.1007/s11239-019-02019.
    PubMed    


  35. WERNLY B, Bhatt DL, Polzin A, Jung C, et al
    Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more.
    J Thromb Thrombolysis. 2019 Dec 3. pii: 10.1007/s11239-019-02007.
    PubMed     Abstract available


  36. ZHOU Y, He W, Zhou Y, Zhu W, et al
    Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2019 Dec 2. pii: 10.1007/s11239-019-02008.
    PubMed     Abstract available


    November 2019
  37. DA COSTA FA, Mala-Ladova K, Lee V, Tous S, et al
    Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.
    J Thromb Thrombolysis. 2019 Nov 28. pii: 10.1007/s11239-019-02000.
    PubMed     Abstract available


  38. PRENTICE A, Ruiz I, Weeda ER
    Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis.
    J Thromb Thrombolysis. 2019 Nov 5. pii: 10.1007/s11239-019-01986.
    PubMed     Abstract available


  39. LIU XH, Gao XF, Chen CF, Chen B, et al
    Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis.
    J Thromb Thrombolysis. 2019 Nov 4. pii: 10.1007/s11239-019-01989.
    PubMed     Abstract available


  40. AMROZE A, Mazor K, Crawford S, O'Day K, et al
    Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.
    J Thromb Thrombolysis. 2019;48:629-637.
    PubMed     Abstract available


  41. WRIGHT JN, Vazquez SR, Kim K, Jones AE, et al
    Assessing patient preferences for switching from warfarin to direct oral anticoagulants.
    J Thromb Thrombolysis. 2019;48:596-602.
    PubMed     Abstract available


    October 2019
  42. VANNUCCHI V, Moroni F, Grifoni E, Marcucci R, et al
    Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke.
    J Thromb Thrombolysis. 2019 Oct 17. pii: 10.1007/s11239-019-01972.
    PubMed     Abstract available


  43. DI GENNARO L, Lancellotti S, De Cristofaro R, De Candia E, et al
    Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy.
    J Thromb Thrombolysis. 2019;48:528-531.
    PubMed     Abstract available


    September 2019
  44. GULILAT M, Keller D, Linton B, Pananos AD, et al
    Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
    J Thromb Thrombolysis. 2019 Sep 28. pii: 10.1007/s11239-019-01962.
    PubMed     Abstract available


    August 2019
  45. WOJSZEL ZB, Kasiukiewicz A
    Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study.
    J Thromb Thrombolysis. 2019 Aug 30. pii: 10.1007/s11239-019-01937.
    PubMed     Abstract available


  46. IKEDA T, Ogawa S, Kitazono T, Nakagawara J, et al
    Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
    J Thromb Thrombolysis. 2019 Aug 20. pii: 10.1007/s11239-019-01934.
    PubMed     Abstract available


  47. RUSSO V, Attena E, Di Maio M, Mazzone C, et al
    Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    J Thromb Thrombolysis. 2019 Aug 5. pii: 10.1007/s11239-019-01923.
    PubMed     Abstract available


    July 2019
  48. SAMOS M, Bolek T, Skornova I, Benko J, et al
    Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?
    J Thromb Thrombolysis. 2019 Jul 1. pii: 10.1007/s11239-019-01910.
    PubMed     Abstract available


    June 2019
  49. MIAO B, Alberts MJ, Bunz TJ, Coleman CI, et al
    Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
    J Thromb Thrombolysis. 2019 Jun 21. pii: 10.1007/s11239-019-01898.
    PubMed     Abstract available


  50. OSMAN M, Kheiri B, Munir MB, Moreland JA, et al
    The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis.
    J Thromb Thrombolysis. 2019 Jun 7. pii: 10.1007/s11239-019-01896.
    PubMed    


  51. KE HH, He Y, Lv XW, Zhang EH, et al
    Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jun 5. pii: 10.1007/s11239-019-01876.
    PubMed     Abstract available


    May 2019
  52. GRUCA MM, Li Y, Kong X, DeCamillo D, et al
    Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2019 May 20. pii: 10.1007/s11239-019-01883.
    PubMed     Abstract available


  53. KHEIRI B, Osman M, Bakhit A, Radaideh Q, et al
    Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.
    J Thromb Thrombolysis. 2019 May 3. pii: 10.1007/s11239-019-01874.
    PubMed    


    April 2019
  54. GUIMARAES PO, Lopes RD, Alexander JH, Thomas L, et al
    International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.
    J Thromb Thrombolysis. 2019 Apr 10. pii: 10.1007/s11239-019-01858.
    PubMed     Abstract available


  55. SCHOAPS RS, Quintili A, Bonavia A, Carr ZJ, et al
    Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 8. pii: 10.1007/s11239-019-01854.
    PubMed     Abstract available


  56. OKISHIGE K, Yamauchi Y, Hanaki Y, Inoue K, et al
    Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 6. pii: 10.1007/s11239-019-01835.
    PubMed     Abstract available


  57. WASHAM JB, Hohnloser SH, Lopes RD, Wojdyla DM, et al
    Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
    J Thromb Thrombolysis. 2019;47:345-352.
    PubMed     Abstract available


    March 2019
  58. AMIN A, Keshishian A, Dina O, Dhamane A, et al
    Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    J Thromb Thrombolysis. 2019 Mar 28. pii: 10.1007/s11239-019-01838.
    PubMed     Abstract available


  59. CROSTA F, Desideri G, Marini C
    Leukoaraiosis is an independent predictor of intracranial hemorrhage in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 14. pii: 10.1007/s11239-019-01839.
    PubMed     Abstract available


  60. KARTAS A, Samaras A, Vasdeki D, Dividis G, et al
    Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 4. pii: 10.1007/s11239-019-01832.
    PubMed     Abstract available


    February 2019
  61. STANKOVIC P, Georgiew R, Frommelt C, Hammel S, et al
    Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
    J Thromb Thrombolysis. 2019 Feb 7. pii: 10.1007/s11239-019-01824.
    PubMed     Abstract available


  62. BJORCK F, Kadhim H, Sjalander A
    Predictors for INR-control in a well-managed warfarin treatment setting.
    J Thromb Thrombolysis. 2019;47:227-232.
    PubMed     Abstract available


    January 2019
  63. HIRSH RACCAH B, Rottenstreich A, Zacks N, Matok I, et al
    Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jan 28. pii: 10.1007/s11239-019-01815.
    PubMed     Abstract available


    December 2018
  64. WANG CL, Wu VC, Lee CH, Kuo CF, et al
    Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
    J Thromb Thrombolysis. 2018 Dec 18. pii: 10.1007/s11239-018-1792.
    PubMed     Abstract available


    November 2018
  65. MASOTTI L, Grifoni E, Dei A, Vannucchi V, et al
    Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.
    J Thromb Thrombolysis. 2018 Nov 23. pii: 10.1007/s11239-018-1775.
    PubMed     Abstract available


  66. HOWE Z, Naville-Cook C, Cole D
    Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1770.
    PubMed     Abstract available


  67. CHOPARD R, Piazza G, Hurwitz S, Fanikos J, et al
    Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1767.
    PubMed     Abstract available


    October 2018
  68. BOLEK T, Samos M, Skornova I, Stanciakova L, et al
    Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    J Thromb Thrombolysis. 2018 Oct 4. pii: 10.1007/s11239-018-1748.
    PubMed     Abstract available


  69. SOKOL J, Nehaj F, Ivankova J, Mokan M, et al
    First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    J Thromb Thrombolysis. 2018;46:393-398.
    PubMed     Abstract available


  70. CAPPELLARI M, Turcato G, Forlivesi S, Micheletti N, et al
    Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score > 2.
    J Thromb Thrombolysis. 2018;46:292-298.
    PubMed     Abstract available


    September 2018
  71. HIRSH RACCAH B, Rottenstreich A, Zacks N, Muszkat M, et al
    Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2018 Sep 8. pii: 10.1007/s11239-018-1738.
    PubMed     Abstract available


    August 2018
  72. MAZUR P, Myc J, Natorska J, Plens K, et al
    Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.
    J Thromb Thrombolysis. 2018;46:193-202.
    PubMed     Abstract available


  73. POLNAK JF, Delate T, Clark NP
    The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.
    J Thromb Thrombolysis. 2018;46:264-270.
    PubMed     Abstract available


  74. SHIROSHITA A, Nakashima K, Tanaka Y, Tateishi A, et al
    Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report.
    J Thromb Thrombolysis. 2018;46:271-273.
    PubMed     Abstract available


    July 2018
  75. JACKSON LR 2ND, Kim S, Shrader P, Blanco R, et al
    Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    J Thromb Thrombolysis. 2018 Jul 26. pii: 10.1007/s11239-018-1715.
    PubMed     Abstract available


  76. AGIRBASLI M
    Quality of direct oral anticoagulant therapy in elderly patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 Jul 25. pii: 10.1007/s11239-018-1717.
    PubMed    


    June 2018
  77. CHI G, Yee MK, Kalayci A, Kerneis M, et al
    Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    J Thromb Thrombolysis. 2018 Jun 26. pii: 10.1007/s11239-018-1703.
    PubMed     Abstract available


  78. KHEIRI B, Haykal T, Abdalla A, Osman M, et al
    Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis.
    J Thromb Thrombolysis. 2018 Jun 15. pii: 10.1007/s11239-018-1694.
    PubMed    


  79. HUGHEY AB, Gu X, Haymart B, Kline-Rogers E, et al
    Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) registry to the RE-LY, ROCKET-AF, and ARISTOTLE
    J Thromb Thrombolysis. 2018 Jun 14. pii: 10.1007/s11239-018-1698.
    PubMed     Abstract available


  80. MONAGLE SR, Hirsh J, Bhagirath VC, Ginsberg JS, et al
    Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada.
    J Thromb Thrombolysis. 2018 Jun 5. pii: 10.1007/s11239-018-1692.
    PubMed     Abstract available


    May 2018
  81. ROSSI AP, Facchinetti R, Ferrari E, Nori N, et al
    Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 May 14. pii: 10.1007/s11239-018-1679.
    PubMed     Abstract available


  82. HOYER C, Filipov A, Neumaier-Probst E, Szabo K, et al
    Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke.
    J Thromb Thrombolysis. 2018;45:529-535.
    PubMed     Abstract available


  83. FASULLO S, Davi S, Cosenza G, Di Franco F, et al
    Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature.
    J Thromb Thrombolysis. 2018;45:588-592.
    PubMed     Abstract available


    April 2018
  84. GRANT SJ, Kothari S, Gimotty PA, Gooneratne NS, et al
    Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    J Thromb Thrombolysis. 2018 Apr 2. pii: 10.1007/s11239-018-1651.
    PubMed     Abstract available


    February 2018
  85. BRUNETTI ND, Tarantino N, De Gennaro L, Correale M, et al
    Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.
    J Thromb Thrombolysis. 2018 Feb 5. pii: 10.1007/s11239-018-1622.
    PubMed     Abstract available


    January 2018
  86. XIANG E, Ahuja T, Raco V, Cirrone F, et al
    Anticoagulation prescribing patterns in patients with cancer.
    J Thromb Thrombolysis. 2018;45:89-98.
    PubMed     Abstract available


    December 2017
  87. RUSSO V, Rago A, Papa AA, D'Onofrio A, et al
    Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
    J Thromb Thrombolysis. 2017 Dec 19. pii: 10.1007/s11239-017-1599.
    PubMed     Abstract available


  88. SHIN H, Cho MC, Kim RB, Kim CH, et al
    Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2017 Dec 2. pii: 10.1007/s11239-017-1590.
    PubMed     Abstract available


    July 2017
  89. PIPILIS A, Makrygiannis S, Anagnostou G, Kaliampakos S, et al
    Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures.
    J Thromb Thrombolysis. 2017;44:9-13.
    PubMed     Abstract available


    June 2017
  90. HELMERT S, Marten S, Mizera H, Reitter A, et al
    Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    J Thromb Thrombolysis. 2017 Jun 22. doi: 10.1007/s11239-017-1519.
    PubMed     Abstract available


    March 2017
  91. STEPPICH B, Dobler F, Brendel LC, Hessling G, et al
    Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2017 Mar 18. doi: 10.1007/s11239-017-1495.
    PubMed     Abstract available


    February 2017
  92. MARSICO F, Cecere M, Parente A, Paolillo S, et al
    Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal.
    J Thromb Thrombolysis. 2017;43:139-148.
    PubMed     Abstract available


    August 2016
  93. ROSWELL RO, Greet B, Shah S, Bernard S, et al
    Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias.
    J Thromb Thrombolysis. 2016;42:179-85.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: